Esketamine - Auris Medical/INSERM/University of Montpellier

Drug Profile

Esketamine - Auris Medical/INSERM/University of Montpellier

Alternative Names: (s)-ketamine; AM-101; Keyzilen

Latest Information Update: 07 Feb 2017

Price : $50

At a glance

  • Originator Auris Medical; INSERM; University of Montpellier I
  • Developer Auris Medical
  • Class Analgesics; Antidepressants; Chlorobenzenes; Cyclohexanones; General anaesthetics; Small molecules
  • Mechanism of Action NMDA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Tinnitus
  • New Molecular Entity No

Highest Development Phases

  • Phase III Tinnitus

Most Recent Events

  • 01 Jan 2017 Auris Medical completes the AMPACT1 trial in Tinnitus in USA and Czech Republic (Intratympanic) (NCT01934010)
  • 01 Dec 2016 Auris Medical completes the phase III AMPACT2 extension trial for Tinnitus in Germany, Hungary, Belgium, Austria, United Kingdom, Poland and Spain (EudraCT2013-001527-39) (NCT02040207)
  • 12 Oct 2016 Updated efficacy data from the phase III TACTT2 trial in Tinnitus released by Auris Medical
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top